Guidelines for naloxone provision upon release from prison and other custodial settings - a hands-on toolkit for policy makers and practitioners on how to set up and run naloxone programmes for overdose prevention upon release from prison and other custodial settings.
The toolkit aim at providing hands-on recommendations for policy makers and practitioners from prison health services on how to promote, initiate and manage interventions related to overdose prevention through naloxone programs and how to organise related training and capacity building.
Kirsten Horsburgh from the Scottish Drugs Forum, author of the guidelines, analysed information and literature available from a number of European countries as well as relying on the Scottish national naloxone programme experience, with particular reference to interventions focusing on people leaving prison.
Prisoners report much higher prevalence rates of drug use and more harmful consumption patterns than the general population. People who use drugs have above-average experiences with the criminal justice system in general, and the prison system and subsequent release situations in particular. Release from prison is associated with increased mortality rates among drug users due to the risk of overdose. The EU-funded project ‘My first 48 hours out’ aimed to address the gaps in continuity of care for long-term drug users in prison and upon release, with a special focus on drug user’s perspectives on needs and challenges upon release.
This visual booklet was produced in the framework of the EU co-funded project “My first 48 hours out” – comprehensive approaches to pre and post prison release interventions for drug users in the criminal justice system”, implemented by the University of Applied Sciences in Frankfurt.
My first 48 hours out” aims at addressing the gaps in the continuity of care for long-term drug users in prison and upon release, by supporting life-saving interventions for the prevention of overdoses and reduction of other risks related to drug use and for the establishment of a treatment path, which does not get interrupted upon release. The booklet complements the “Guidelines for naloxone provision upon release from prison and other custodial settings”, which were also produced by the project
Please note: there are various version of this report if you click on the file!
This is the second civil society-led monitoring report produced by Correlation – European Harm Reduction Network (C-EHRN) within the context of our operational grant from the European Commission. The purpose of this report is to enrich the information and knowledge base of harm reduction interventions in Europe from the viewpoint of civil society organisations. We believe that this approach is a necessary, and useful, contribution to the development of drug policy in the region. We learned a lot from the former process and the 2019 edition and modified the approach, the focus and certain questions to enable respondents to report closer to their own experiences. Consequently, the information provided in this report sometimes represents the situation in a particular city or region and informs us as to the experiences of a specific organisation in the field. Such ‘real life’ information can contribute significantly to an understanding of the advantages, barriers and challenges of drug policy. Even stronger, we directly approached representatives of networks and organizations of people who use drugs to share their view on the developments with us. 2020, however, was not a regular year and the world wide pandemic had its influence on people, organisations and the care system in general. Accordingly, we added a section on the impact of COVID-19 on harm reduction services and we will continue to measure this impact. We will use the insights and information collected in this report within our advocacy efforts to strengthen harm reduction policies in Europe and, we hope, our partners and contributors will do the same in their environment at a regional and national level. More than one hundred organisations and individuals from 34 European countries have contributed to the collection of data with an amazingly high response rate; we thank all contributors for their great work and commitment. Without their engagement, this work would never have been undertaken at all. In particular, we would like to thank the authors of this report, Rafaela Rigoni, Tuukka Tammi, Daan van der Gouwe, and Victoria Oberzil, who were supported by the coordinators of the expert groups and the reviewers of this report. We are also grateful to HRI and Robert Czack for contributing with a chapter to this report. A special thanks to Dagmar Hedrich and her EMCDDA colleagues for their ongoing and patient support. We thank the European Commission, DG Sante, for their financial support and to the Regenboog Groep, Amsterdam, for their ongoing support of Correlation – European Harm Reduction Network